1. CTIM-15. FIRST-IN-HUMAN PHASE 1 STUDY OF CD200 ACTIVATION RECEPTOR-LIGAND (CD200AR-L) AND ALLOGENEIC TUMOR LYSATE VACCINE IMMUNOTHERAPY FOR RECURRENT GLIOBLASTOMA: INITIAL RESULTS FROM AN ONGOING CLINICAL TRIAL. (12th November 2021) Authors: Neil, Elizabeth; Eaton, Anne; Lunn, Shannon; Nelson, Kristen; Greengard, Emily; Moertel, Christopher; Olin, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗